Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares traded up 4.9% during trading on Friday . The stock traded as high as $5.77 and last traded at $5.70. 922,095 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 1,640,261 shares. The stock had previously closed at $5.43.

Analyst Upgrades and Downgrades

Several research analysts have commented on XERS shares. HC Wainwright reissued a “buy” rating and issued a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners raised their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th. Finally, Craig Hallum lifted their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $5.92.

Xeris Biopharma Trading Up 7.0 %

The business has a 50-day moving average price of $3.88 and a 200-day moving average price of $3.41. The stock has a market cap of $894.39 million, a PE ratio of -12.91 and a beta of 2.32.

Insider Buying and Selling at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at approximately $7,349,559.30. The trade was a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.56% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Xeris Biopharma

A number of institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its stake in Xeris Biopharma by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after acquiring an additional 2,954 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Xeris Biopharma by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock valued at $273,000 after purchasing an additional 3,447 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Xeris Biopharma by 31.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company’s stock valued at $55,000 after acquiring an additional 3,847 shares during the last quarter. GPS Wealth Strategies Group LLC lifted its stake in shares of Xeris Biopharma by 6.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock worth $227,000 after buying an additional 3,900 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in Xeris Biopharma by 31.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock valued at $78,000 after purchasing an additional 5,500 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.